MedPath

Bonerge Announces the New 108 Person Clinical Trial: Exploring Skin and Organ Anti-Aging Innovations

6 months ago1 min read
In this clinical trial, Bonerge is examining the skin anti-aging effects of individual ingredients, as well as the combination of three ingredients to explore their synergistic effects on skin health and anti-aging. The trial is progressing as planned and is expected to conclude in March 2025. Bonerge hopes that this study will offer valuable evidence for the anti-aging market, potentially leading to the application of Senolytics in skin health and broader anti-aging treatments.
References:
  • Chase M. Carver, et al. IL-23R is a senescence-linked circulating and tissue biomarker of aging. Nature Aging, Dec 2024.
  • Researchers discover an aging and inflammation biomarker - Mayo Clinic News Network
  • Matthew J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36 (2018).
  • Wenjie Liu, et al. Urolithin A protects human dermal fibroblasts from UVA-induced photoaging through NRF2 activation and mitophagy. J Photochem Photobiol B. 2022 Jul.
  • Brown, Lisa, et al. L-Ergothioneine and Its Protective Role in Cellular Health. Journal of Clinical Nutrition, vol 56.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

© Copyright 2025. All Rights Reserved by MedPath